An entire-population analysis of nationwide trends in cancer incidence and mortality in hungary

BACKGROUND: Hungary faces a persistently high cancer burden, yet detailed, longitudinal assessments of population-level trends across major tumor types remain limited. Understanding shifts in incidence, mortality, and prevalence is essential for refining screening strategies and healthcare-system planning. METHODS: Nationwide oncology records from the Hungarian National Health Insurance Fund (NEAK), completely covering the entire population of appr. 10 million, were analyzed for the five most common cancer types: breast (C50), colorectal (C18), lung (C34), prostate (C61), and stomach (C16). Annual incidence and mortality were calculated separately, while prevalence values represent two-year aggregated national counts. All metrics were summarized across both sexes and all age groups. Data were validated against established statistics from the Hungarian National Cancer Registry. Temporal changes represent differences between national baseline figures from 2018 and recent data through 2024. RESULTS: The five tumor types exhibited consistent directional shifts nationwide. Breast cancer incidence increased 4.98%, mortality rose 42.69%, and crude prevalence increased from 37,887 to 39,773. Lung cancer incidence declined 10.61%, mortality decreased 3.02%, and crude prevalence fell from 31,829 to 28,452. Colorectal cancer incidence decreased 2.29%, mortality increased 21.24%, and crude prevalence declined from 27,589 to 26,956. Prostate cancer incidence rose 9.51%, mortality increased 32.55%, and crude prevalence increased from 19,046 to 20,858. Stomach cancer incidence increased 16.45%, mortality decreased 16.57%, and crude prevalence fell from 5,770 to 4,814. These patterns were observed across both sexes and all age groups, indicating broad population-level shifts rather than age- or sex-specific effects. A web tool was established to visualize these trends and is available at www.epidemplot.com. CONCLUSIONS: Hungarian nationwide data reveal substantial mortality increases for breast, prostate, and colorectal cancers despite divergent incidence trends, indicating critical gaps in early detection and treatment pathways. Lung cancer demonstrated coordinated declines in both incidence and mortality. These findings highlight the need for targeted improvements in screening programs and care coordination for specific tumor types. This standardized framework enables ongoing national surveillance and expansion to additional malignancies.